- Home
- DHAI vs CNTB Comparison
DHAI vs CNTB Comparison
Compare DHAI & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHAI
- CNTB
- Stock Information
- Founded
- DHAI 2007
- CNTB 2012
- Country
- DHAI United States
- CNTB United States
- Employees
- DHAI N/A
- CNTB N/A
- Industry
- DHAI
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- DHAI
- CNTB Health Care
- Exchange
- DHAI NYSE
- CNTB Nasdaq
- Market Cap
- DHAI 49.1M
- CNTB 55.2M
- IPO Year
- DHAI N/A
- CNTB 2021
- Fundamental
- Price
- DHAI $0.22
- CNTB $0.57
- Analyst Decision
- DHAI
- CNTB Strong Buy
- Analyst Count
- DHAI 0
- CNTB 1
- Target Price
- DHAI N/A
- CNTB $8.00
- AVG Volume (30 Days)
- DHAI 597.4K
- CNTB 50.6K
- Earning Date
- DHAI 02-14-2025
- CNTB 03-31-2025
- Dividend Yield
- DHAI N/A
- CNTB N/A
- EPS Growth
- DHAI N/A
- CNTB N/A
- EPS
- DHAI N/A
- CNTB N/A
- Revenue
- DHAI $69,573,000.00
- CNTB $26,033,000.00
- Revenue This Year
- DHAI N/A
- CNTB $997.61
- Revenue Next Year
- DHAI N/A
- CNTB N/A
- P/E Ratio
- DHAI N/A
- CNTB N/A
- Revenue Growth
- DHAI 5.40
- CNTB N/A
- 52 Week Low
- DHAI $0.22
- CNTB $0.55
- 52 Week High
- DHAI $3.67
- CNTB $2.66
- Technical
- Relative Strength Index (RSI)
- DHAI 28.55
- CNTB 26.20
- Support Level
- DHAI $0.24
- CNTB $0.80
- Resistance Level
- DHAI $0.28
- CNTB $0.84
- Average True Range (ATR)
- DHAI 0.04
- CNTB 0.08
- MACD
- DHAI 0.01
- CNTB -0.02
- Stochastic Oscillator
- DHAI 2.28
- CNTB 6.34
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.